Centene Corporation
CNC
$41.09
+5.55%
Centene Corporation is a leading managed care organization specializing in government-sponsored healthcare plans, primarily Medicaid, Medicare, and individual exchange plans, serving approximately 20 million medical members. The company is a dominant player in the Medicaid managed care market, leveraging its scale and expertise in administering complex, government-funded health programs. The current investor narrative is dominated by the company's volatile financial performance, highlighted by a significant net loss in its most recent quarter, juxtaposed against a broader sector tailwind from favorable regulatory updates on Medicare Advantage payments. This creates a debate between near-term profitability challenges and the long-term stability of its core government-backed revenue streams.…
CNC
Centene Corporation
$41.09
Investment Opinion: Should I buy CNC Today?
Rating & Thesis: Hold. Centene is a deep-value, high-risk turnaround story where extreme valuation discount is counterbalanced by a severe and ongoing profitability crisis, resulting in a neutral risk/reward profile at the current price, consistent with the analyst consensus of 'Neutral'.
Supporting Evidence: The primary valuation metric, the Price-to-Sales ratio of 0.10, is at an 85%+ discount to typical industry multiples, suggesting significant embedded upside if margins normalize. Revenue growth remains robust at 21.86% YoY, demonstrating the durability of its core government-backed business. However, this is completely offset by negative profitability trends, with a TTM net margin of -3.43% and an operating margin of -3.91%. The forward P/E of 9.4x, based on estimated EPS of $9.41, appears cheap but is contingent on a dramatic earnings recovery that is not yet evident in recent results.
Risks & Conditions: The two biggest risks are 1) further margin deterioration leading to sustained losses, and 2) the stock remaining a 'value trap' despite its cheap multiples. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of positive net income and gross margin stabilization above 16%. It would downgrade to a Sell if quarterly net losses persist near or exceed the -$1B level seen in Q4 2025 or if revenue growth decelerates into the single digits. The stock is undervalued on a sales basis relative to its history and peers, but fairly valued (or even overvalued) on an earnings basis given the current lack of profits.
Sign up to view all
CNC 12-Month Price Forecast
The outlook for CNC is bifurcated, with the path determined solely by the resolution of its profitability crisis. The base case (60% probability) of range-bound trading is most likely, as the market awaits concrete evidence of a turnaround. The bull case offers substantial upside (to $64) but requires a swift and credible earnings recovery that recent quarters have not shown. The bear case risk is meaningful, with a -34% downside to the 52-week low of $25.08. The stance would upgrade to bullish on two consecutive quarters of positive net income and margin expansion. It would turn bearish on a breakdown below $32 accompanied by another large quarterly loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $53.42 and implied upside of +30.0% versus the current price.
Average Target
$53.42
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$33 - $53
Analyst target range
Analyst coverage is limited, with only 7 analysts providing estimates, and the institutional ratings show a consensus leaning neutral, with recent actions from firms like JP Morgan, Mizuho, and Morgan Stanley all maintaining 'Neutral' or 'Equal Weight' stances. The average revenue estimate for the upcoming period is $210.95 billion, with a range from $204.43 billion to $216.95 billion, but a consensus price target is not provided in the data, making an implied upside calculation impossible. The wide revenue estimate range signals high uncertainty among analysts regarding the company's near-term financial trajectory. The pattern of neutral ratings from major firms, coupled with the lack of a clear price target, indicates limited institutional conviction and suggests the stock is in a 'show-me' phase where analysts await clearer signs of a profitability turnaround before adopting more bullish stances.
Bulls vs Bears: CNC Investment Factors
The investment debate for Centene is a classic clash between deep value and deteriorating fundamentals. The bull case, anchored by an extreme valuation discount (PS of 0.10), strong revenue growth (21.86% YoY), and robust free cash flow ($4.32B TTM), currently holds stronger quantitative evidence of mispricing. However, the bear case presents a powerful qualitative counter: severe and worsening profitability losses, catastrophic stock momentum, and a complete lack of analyst conviction. The single most important tension is whether the company's massive scale and government-backed revenue streams can overcome its acute profitability crisis. The resolution hinges on management's ability to stabilize margins; if they fail, the deep value argument evaporates, but if they succeed, the current price represents a profound mispricing.
Bullish
- Extreme Valuation Discount: The stock trades at a Price-to-Sales ratio of 0.10 and an EV/Sales of 0.10, representing a steep discount to the typical healthcare plan provider multiple of >0.5x. This valuation is at the very bottom of its multi-year historical range, suggesting market pessimism is fully priced in, offering a significant margin of safety.
- Strong Revenue Growth & Scale: Q4 2025 revenue grew 21.86% YoY to $49.73B, driven by its dominant Medicaid segment ($37.65B). The company serves 20 million members, providing a stable, government-backed revenue base that is less sensitive to economic cycles, as evidenced by its low beta of 0.59.
- Robust Free Cash Flow Generation: Despite massive accounting losses, the company generated $4.32B in TTM free cash flow. This indicates reported net losses contain substantial non-cash charges and provides a crucial liquidity buffer, allowing the company to fund operations and navigate its profitability challenges.
- Sector Tailwind from Medicare Payments: Recent news highlights a larger-than-expected 2027 Medicare Advantage payment increase from CMS, boosting sentiment across the managed care sector. As a participant in Medicare (5% of membership), Centene stands to benefit from this improved revenue visibility.
Bearish
- Severe & Worsening Profitability Crisis: Profitability has collapsed, with Q4 2025 showing a net loss of -$1.10B and a gross margin of 15.18%, down from 16.38% in Q3. The company swung from a $1.31B profit in Q1 2025 to massive losses in Q3 (-$6.63B) and Q4, indicating deep operational issues.
- Deep Negative Momentum & Underperformance: The stock is down 37.12% over the past year and trades near 40% of its 52-week range ($38.17 vs. high of $64.15). It has significantly underperformed the S&P 500 by 72 percentage points on a 1-year relative strength basis, reflecting a severe loss of investor confidence.
- Analyst Apathy & High Uncertainty: Analyst coverage is limited to 7 firms, with consensus ratings neutral and no clear price target provided. The wide revenue estimate range for the upcoming period ($204.43B to $216.95B) signals high uncertainty and a lack of conviction in a near-term turnaround.
- Margin Compression & Cost Pressures: Gross margin has been volatile and compressed to 12.24% on a TTM basis, while the operating margin is negative at -3.91%. This suggests the company is struggling to translate robust revenue growth into profits, likely due to rising medical costs or administrative inefficiencies.
CNC Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -37.12%, significantly underperforming the broader market. As of the latest close at $38.17, the price is trading at approximately 40% of its 52-week range ($25.08 to $64.15), positioning it much closer to its annual lows, which suggests a deep value opportunity but also reflects severe negative momentum and fundamental concerns. Recent momentum shows a modest short-term recovery, with a 1-month gain of 5.56%, yet this is overshadowed by a 3-month decline of -16.57%, indicating the recent uptick is a tentative bounce within a larger bearish context and has occurred amid significant market underperformance, as evidenced by a -1.80 relative strength reading over the past month. Key technical support is firmly established at the 52-week low of $25.08, while resistance lies near the 52-week high of $64.15; a sustained move above the recent recovery highs near $47 would be needed to signal a potential trend reversal. The stock's beta of 0.59 indicates it is approximately 41% less volatile than the S&P 500, which is unusually low for a healthcare stock and may reflect its defensive, government-reliant business model, but also suggests limited upside participation in strong market rallies.
Beta
0.59
0.59x market volatility
Max Drawdown
-60.8%
Largest decline past year
52-Week Range
$25-$64
Price range past year
Annual Return
-33.9%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +24.6% | +8.5% |
| 3m | -10.8% | +2.8% |
| 6m | +20.6% | +4.6% |
| 1y | -33.9% | +32.3% |
| ytd | -1.7% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Revenue growth remains robust on a year-over-year basis, with Q4 2025 revenue of $49.73 billion representing a 21.86% increase from the prior year, primarily driven by the Medicaid segment which contributed $37.65 billion. However, this top-line strength is completely offset by severe profitability issues, as the same quarter saw a net income loss of -$1.10 billion and a gross margin of only 15.18%, which compressed from 16.38% in Q3 2025. The company's profitability has deteriorated sharply through 2025, swinging from a net income of $1.31 billion in Q1 to massive losses in Q3 (-$6.63 billion) and Q4, indicating significant operational or cost pressures. The balance sheet shows a manageable debt-to-equity ratio of 0.94, and the company maintains a strong liquidity position with a current ratio of 1.68. Critically, the company generated positive free cash flow of $4.32 billion on a trailing-twelve-month basis, which provides a crucial buffer and suggests the reported net losses contain significant non-cash charges, allowing it to fund operations internally despite the accounting losses.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.10, and the forward-looking valuation can be inferred from the Enterprise Value-to-Sales (EV/Sales) of 0.10, indicating the market is valuing the company at a deep discount to its revenue base. Compared to typical healthcare plan providers, which often trade at PS ratios above 0.5x, Centene's approximately 0.10x multiple represents a steep discount to the industry, which may be justified by its current lack of profitability and margin volatility but could also signal a significant undervaluation if a turnaround materializes. Historically, the stock's own PS ratio has fluctuated widely, from a high near 1.48 in late 2021 to the current level of 0.10; trading at the very bottom of its multi-year historical range suggests the market is pricing in extreme pessimism, either presenting a deep value opportunity or anticipating further fundamental deterioration.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The paramount risk is the company's severe and volatile profitability. Net income swung from +$1.31B in Q1 2025 to -$6.63B in Q3, with Q4 posting another -$1.10B loss. Gross margin compression from 16.38% in Q3 to 15.18% in Q4 indicates persistent cost pressures, likely from medical cost trends or pricing missteps in its government contracts. While free cash flow remains positive ($4.32B TTM), continued net losses could eventually strain the balance sheet, despite a currently manageable debt-to-equity of 0.94.
Market & Competitive Risks: The stock's valuation, while deeply discounted, carries the risk of a 'value trap' if profitability does not recover. Trading at a PS ratio of 0.10 versus a sector norm above 0.5x, the discount is justified by current losses but could persist indefinitely. Competitive pressure in the Medicaid and Medicare Advantage markets could further squeeze margins. The stock's low beta (0.59) suggests defensive characteristics but also implies it may not fully benefit from sector-wide positive catalysts, like the recent favorable Medicare payment updates.
Worst-Case Scenario: The worst-case scenario involves a continuation of the Q3 2025 catastrophe, where operational missteps lead to another massive quarterly loss exceeding -$6B, triggering a crisis of confidence, credit rating downgrades, and a potential exodus of state Medicaid contracts. In this scenario, the stock could re-test its 52-week low of $25.08, representing a downside of approximately -34% from the current price of $38.17. The historical max drawdown of -60.79% provides a precedent for such severe losses during periods of fundamental stress.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company may fail to stem its losses, as seen in the -$1.10B Q4 2025 net income. 2) Value Trap Risk: The stock may remain cheap indefinitely if margins do not recover, despite its low PS ratio. 3) Operational Risk: Inability to manage medical costs within government contract pricing could lead to further margin compression and potential contract losses. 4) Sentiment Risk: The stock has severe negative momentum (1-year relative strength of -72) and low analyst conviction, which can perpetuate underperformance regardless of fundamentals.
The 12-month forecast is highly scenario-dependent due to the company's volatile fundamentals. The base case (60% probability) sees the stock trading between $38 and $48 as it works through its profitability challenges. The bull case (25% probability), driven by a successful turnaround, targets a range of $55 to $64, aligning with its 52-week high. The bear case (15% probability) risks a decline to the $25 to $32 range, re-testing the 52-week low. The most likely outcome is the base case, which assumes slow, uneven progress on margins but no catastrophic new setbacks.
CNC is profoundly undervalued on a sales basis but arguably overvalued on an earnings basis, creating a paradox. Its Price-to-Sales ratio of 0.10 is approximately 80% below typical healthcare plan provider multiples, suggesting extreme undervaluation relative to its revenue base. However, with negative net income and a trailing P/E of -3.0, the market is assigning no value to its current earnings power. The forward P/E of 9.4x is cheap but entirely dependent on a dramatic earnings recovery to an estimated $9.41 EPS. The valuation implies the market expects either a significant turnaround or permanent margin impairment.
CNC is a high-risk, high-potential-reward stock that is only a good buy for a specific type of investor. For risk-averse or growth-focused investors, it is not a good buy due to its severe profitability crisis and catastrophic stock performance (-37% over the past year). For deep-value, contrarian investors with a long time horizon, the extreme valuation discount (PS of 0.10) and strong free cash flow ($4.32B) may present a compelling opportunity, but only if they are prepared to withstand further volatility and potential downside to the $25 support level. The lack of analyst conviction underscores the high uncertainty.
CNC is unsuitable for short-term trading due to its low beta (0.59), which limits volatility-driven gains, and its current lack of positive catalysts. It is strictly a long-term, multi-year investment for investors betting on a fundamental turnaround. The deep-value thesis requires time for management to execute operational fixes and for the market to recognize the recovery. A minimum holding period of 2-3 years is suggested to allow for this process. The stock does not pay a dividend, so the entire return is dependent on capital appreciation from a successful re-rating.